DEERFIELD, Ill.--(BUSINESS WIRE)--Dade Behring Inc. (NASDAQ:DADE) has received clearance from the U.S. Food and Drug Administration (FDA) for use of its MicroScan® Synergies plus™ Gram-positive panels. The new technology used in the panels allows for rapid two-hour identification of bacteria and same-day test results for detecting certain antibiotic-resistant bacteria that cause serious health threats in a hospital environment. Some of the antibiotic-resistant bacteria that may be identified on the same-day tested are:
